Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis.
Rozemeijer R, van Muiden IG, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Doevendans PA, Voskuil M, Stella PR. Rozemeijer R, et al. Among authors: rittersma sz. Catheter Cardiovasc Interv. 2019 Jul 1;94(1):61-69. doi: 10.1002/ccd.28041. Epub 2019 Jan 2. Catheter Cardiovasc Interv. 2019. PMID: 30604493 Free PMC article.
Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention.
Monraats PS, Rana JS, Nierman MC, Pires NM, Zwinderman AH, Kastelein JJ, Kuivenhoven JA, de Maat MP, Rittersma SZ, Schepers A, Doevendans PA, de Winter RJ, Tio RA, Frants RR, Quax PH, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: rittersma sz. J Am Coll Cardiol. 2005 Sep 20;46(6):1093-100. doi: 10.1016/j.jacc.2005.05.071. J Am Coll Cardiol. 2005. PMID: 16168296 Free article.
Rationale and design of amphilimus sirolimus-eluting stents versus zotarolimus-eluting stents in all-comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial.
Rozemeijer R, Stein M, Frambach P, Voskuil M, Kraaijeveld AO, Rodríguez-Olivares R, Timmers L, Pereira B, Rittersma SZ, Agostoni P, Doevendans PA, Stella PR. Rozemeijer R, et al. Among authors: rittersma sz. Catheter Cardiovasc Interv. 2018 Feb 15;91(3):410-416. doi: 10.1002/ccd.27142. Epub 2017 May 22. Catheter Cardiovasc Interv. 2018. PMID: 28544782
Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry.
Rozemeijer R, Benedetto D, Kraaijeveld AO, Voskuil M, Stein M, Timmers L, Rittersma SZ, Agostoni P, Doevendans PA, Stella PR. Rozemeijer R, et al. Among authors: rittersma sz. Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):521-525. doi: 10.1016/j.carrev.2017.10.011. Epub 2017 Oct 26. Cardiovasc Revasc Med. 2018. PMID: 29137966
Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
Rozemeijer R, Stein M, Voskuil M, van den Bor R, Frambach P, Pereira B, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Agostoni P, Roes KC, Doevendans PA, Stella PR; ReCre8 Study Investigators. Rozemeijer R, et al. Among authors: rittersma sz. Circulation. 2019 Jan 2;139(1):67-77. doi: 10.1161/CIRCULATIONAHA.118.037707. Circulation. 2019. PMID: 30586704 Clinical Trial.
34 results